Avanos (AVNS) Q4 2025: $30M Tariff Headwind Drives Supply Chain Pivot, Specialty Nutrition Outpaces Market
Tariff-driven cost pressure dominated Avanos’ Q4, but proactive supply chain shifts and portfolio focus helped offset headwinds. Specialty Nutrition Systems (SNS) led growth, while pain management showed mixed results and margin resilience. With China exit milestones and new product launches ahead, operational discipline and targeted M&A remain central to the 2026 strategy.
Summary
- Supply Chain Realignment: China exit for syringe manufacturing by June will materially reduce tariff exposure.
- Portfolio Sharpening: Divestitures and the Nexus acquisition reinforce Avanos’ pivot toward higher-growth, higher-margin segments.
- Margin Recovery: Gross margin momentum is expected to resume in H2 2026 as tariff mitigation takes effect.
Performance Analysis
Avanos delivered Q4 and full-year results at the high end of revised guidance, driven by strong execution in its core Specialty Nutrition Systems (SNS) segment, which grew over 8% organically for the year. SNS, which encompasses long-term, short-term, and neonatal enteral feeding, now anchors the company’s growth profile, with short-term feeding and neonatal solutions both posting above-market gains. The successful UK Go Direct transition and CoreTrack and CoreGrip product adoption were key contributors.
Pain Management and Recovery (PM&R) showed normalized organic sales growth of 2.3%, led by double-digit expansion in radiofrequency ablation (RFA), offset by continued surgical pain softness as reimbursement tailwinds lagged expectations. Segment profitability improved by 270 basis points despite tariff drag, reflecting cost discipline and portfolio pruning. Divestitures of the hyaluronic acid and IV therapy businesses, and the tuck-in of Nexus Medical, further concentrated Avanos’ portfolio on segments with stronger clinical and economic value.
- Tariff Impact: $30M in 2026 tariff expense, mostly China-related, will be mitigated by mid-year supply chain transition.
- Operating Leverage: Cost transformation and efficiency initiatives are driving earnings growth above top-line expansion.
- Free Cash Flow Strength: $43M full-year free cash flow supports both M&A and organic investments, with leverage below one turn.
While gross margin is expected to pause in 2026 due to tariff timing, management anticipates improvement in the second half and into 2027 as mitigation actions take hold. The company’s ability to deliver on guidance despite external cost shocks demonstrates operational resilience and strategic clarity.
Executive Commentary
"While the impact of tariffs in 2025 obscured the profitability of the company, our team took steps to mitigate their impact, and we will see the benefits of those measures starting this year."
Dave Pacitti, Chief Executive Officer
"Our balance sheet remains strong and continues to provide us with strategic flexibility, with $90 million of cash on hand and $100 million of debt outstanding as of December 31st."
Scott Gallivan, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Supply Chain Diversification and Tariff Mitigation
Avanos is executing a full exit from China syringe manufacturing by June 2026, shifting production to Mexico and Southeast Asia. This initiative, combined with USMCA (United States-Mexico-Canada Agreement) and Nairobi Protocol exemptions, is designed to remove the majority of tariff risk from the portfolio. Management’s high confidence in this timeline signals reduced cost volatility ahead and a structurally improved margin profile post-transition.
2. Portfolio Focus and Rationalization
The company is doubling down on higher-growth, higher-margin businesses, specifically SNS and RFA, while divesting underperforming assets such as hyaluronic acid injections and IV therapy. The acquisition of Nexus Medical, a neonatal solutions provider, fits seamlessly into the existing sales channel and is expected to deliver double-digit growth in 2026. This approach sharpens Avanos’ clinical value proposition and capital allocation discipline.
3. Cost Efficiency and Operating Leverage
Recent cost containment actions and SG&A discipline are delivering operating leverage, with earnings growth outpacing revenue expansion. R&D spending is being optimized through a mix of internal and outsourced projects, maintaining innovation momentum without inflating overhead. Management remains vigilant in evaluating and improving or exiting any underperforming businesses.
4. Commercial Execution and Product Innovation
Strong commercial execution in SNS, particularly with the expansion of CoreTrack and CoreGrip, is driving above-market growth. The pipeline includes a next-generation product launch in Q4 2026, supporting continued share gains. The integration of Nexus Medical is exceeding expectations, leveraging Avanos’ established NICU (Neonatal Intensive Care Unit) channel.
5. Capital Deployment and Balance Sheet Strength
With leverage below one turn and robust free cash flow, Avanos is positioned to fund both organic initiatives and targeted M&A. CapEx will remain elevated in H1 2026 due to the China exit, but is expected to normalize thereafter. This financial flexibility underpins ongoing portfolio transformation and growth investments.
Key Considerations
This quarter underscores Avanos’ transition from a diversified medical device portfolio toward a focused, margin-driven medtech platform. The company’s ability to navigate tariff shocks, execute on supply chain pivots, and sustain above-market growth in SNS signals a maturing operating model.
Key Considerations:
- Tariff Phase-Out Timeline: Watch for confirmation of China exit by June and related gross margin inflection in H2 2026.
- Portfolio Mix Evolution: Ongoing divestitures and tuck-in acquisitions will continue to reshape segment exposure and risk profile.
- RFA and Neonatal Growth Trajectory: Sustained double-digit growth in these areas is critical to offsetting surgical pain softness.
- Cost Discipline Sustainability: Execution on cost containment and SG&A leverage will determine the durability of earnings expansion.
- Product Launch and Pipeline Execution: Next-generation product launches and successful Nexus integration are key to maintaining commercial momentum.
Risks
Tariff policy uncertainty remains a near-term risk, particularly if regulatory timelines or exemptions shift. Gross margin recovery depends on flawless execution of the China exit, while any delays or supply chain disruptions could pressure profitability. Competitive intensity in core segments, reimbursement lag for surgical pain, and integration risk for new acquisitions also warrant close monitoring.
Forward Outlook
For Q1 and full-year 2026, Avanos guided to:
- Net sales of $700 to $720 million, with SNS segment growing mid to high single digits organically, PM&R low to mid single digits.
- Adjusted diluted EPS of $0.90 to $1.10, reflecting $30 million in tariff costs concentrated in H1.
Management expects:
- Gross margin improvement resuming in H2 2026 as tariff mitigation is realized.
- CapEx of $25 million, elevated in H1 for supply chain transition then normalizing.
Takeaways
Avanos’ Q4 and FY25 results highlight the company’s operational resilience and strategic focus amid external cost shocks.
- Tariff Mitigation Execution: The China exit and supply chain reconfiguration are critical levers for restoring gross margin and reducing cost volatility.
- Portfolio Sharpening: Divestitures and the Nexus acquisition reinforce the pivot toward higher-growth, higher-margin segments, particularly in specialty nutrition and neonatal care.
- Margin Expansion Watchpoint: Investors should monitor gross margin inflection in H2 2026 and sustained cost discipline as key signals of execution quality.
Conclusion
Despite a challenging tariff environment, Avanos exited 2025 as a more focused, operationally disciplined medtech platform. With supply chain pivots and portfolio realignment tracking to plan, the company is positioned for margin recovery and strategic growth in 2026 and beyond.
Industry Read-Through
Avanos’ rapid supply chain realignment and tariff mitigation strategy signal a broader medtech trend toward regionalized manufacturing and risk diversification. Peers facing similar tariff and regulatory headwinds may need to accelerate supply chain pivots or seek exemptions to protect margin structure. Portfolio rationalization and targeted tuck-in M&A are likely to remain prevalent as companies concentrate on segments with sustainable growth and defensible clinical value. Reimbursement delays in surgical pain and the rising importance of neonatal and specialty nutrition solutions highlight shifting demand patterns and payer focus across the sector.